Skip to main
ATRC
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure Inc. reported fourth-quarter revenues of $124.3 million, reflecting a year-over-year increase of 16.6%, which surpassed expectations by approximately $4 million. The company's research and development expenses represented 28.1% of sales, up significantly year-over-year, driven by a notable $12 million upfront payment for a co-development agreement, indicating robust investment in innovation. Additionally, an EBITDA margin of 10.2% marked a substantial improvement of 570 basis points year-over-year, signalling positive trends in profitability and operational efficiency that contribute to a favorable long-term outlook for the company.

Bears say

AtriCure faces several financial risks, including disappointing sales from its EPi-Sense/Convergent products and expectations of lower revenues from Open Ablation and AtriClip sales, contributing to a negative outlook. The company's revenue growth is projected to decrease to under 11%, with notable slowdowns in key segments such as Minimally Invasive Ablation, Appendage Management, and Pain Management, compounded by competition from Medtronic's LAA device. Furthermore, AtriCure's gross and operating margins have both declined year-over-year, indicating unfavorable trends in profitability despite a slight improvement in adjusted EBITDA margin.

AtriCure (ATRC) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 14 analysts, AtriCure (ATRC) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.